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doi:10.1016/j.ejvs.2009.12.001Abstract Critical limb ischemia (CLI) continues to form a substantial burden on Western
health care. Despite recent advances in surgical and radiological vascular techniques, a large
number of patients is not eligible for these revascularisation procedures and faces amputation
as their ultimate treatment option. Growth factor therapy and stem cell therapy e both ther-
apies focussing on augmenting postnatal neovascularisation e have raised much interest in the
past decade. Based on initial pre-clinical and clinical results, both therapies appear to be
promising strategies to augment neovascularisation and to reduce symptoms and possibly
prevent amputation in CLI patients. However, the underlying mechanisms of postnatal neovas-
cularisation are still incompletely understood. Both fundamental research as well as large ran-
domised trials are needed for further optimisation of these treatment options, and will
hopefully lead to needed advances in the treatment of no-option CLI patients in the near
future.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Peripheral arterial disease (PAD) is a growing health-care
problem. A prevalence ranging from 3% to 10% has been
reported for the general population,1 increasing up to 29%
in primary health-care populations.2 These figures are likely
to increase in the coming years, due to improving life
expectancy of the Westernised population,3 and increasing
prevalence of risk factors such as diabetes and obesity.
Patients with PAD experience a high risk of cardiovasculareting 3e6 September, 2009,
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ty for Vascular Surgery. Publisheevents (i.e., myocardial infarction and stroke),4,5 which
increases with increasing severity of limb symptoms.1
Critical limb ischaemia (CLI), defined as chronic rest pain
or tissue necrosis caused by progressive PAD, is thus asso-
ciated with the highest cardiovascular risk.
Despite its relatively low incidence at 0.05e0.1% per
year,1,6 CLI imposes a disproportionately large medical and
economical burden on Western health care. It is associated
with surgery, hospitalisation and poor quality of life (QoL).7,8
In Europe and North America, there are 413 000 hospital
discharges of patients with chronic PAD annually1; in the
Netherlands, CLI has a reported prevalence between 0.04%
and 0.1%, and leads to approximately 1700 hospital admis-
sions per year, with an average stay of 25 days. Amputation
is the most common reason for admission (57% of the
admissions).9 QoL scores of CLI patients have been reportedd by Elsevier Ltd. All rights reserved.
Stem Cell Therapy in PAD S39to be worse than scores obtained from patients with cancer
and chronic heart disease.8,10
The prognosis for CLI patients is poor, with 5-years
survival rates of 50% or less.11,12 The presence of cardio-
vascular risk factors and co-morbidity importantly
contributes to reduced survival. Treatment of CLI patients
should therefore not only aim at relieving symptoms of CLI
but also at strict cardiovascular risk-factor management to
prevent progression of systemic atherosclerosis. Although,
for some patient groups, primary amputation is considered
the best choice of treatment,13 full mobility after ampu-
tation is only achieved in 25e50% of patients, whereas
perioperative mortality is estimated to be 5e20%, and
a second amputation is required in approximately 30% of
patients.14 For most CLI patients, limb salvage therefore
remains the primary goal of contemporary treatment.13
Despite the rapidly developing radiological and surgical
intervention techniques, the therapeutic options in CLI
patients are limited: approximately 40% of the patients are
not eligible for surgical or radiological revascularisation,
either due to the extent or location of atherosclerotic
lesions or due to extensive co-morbidity.15,16 No effective
pharmacological therapy is currently available.17 New limb-
salving treatment options for CLI are therefore being
explored. Therapies focussing on (the stimulation of)
postnatal neovascularisation have raised much interest in
the past decade. Here, we discuss the current standing of
these therapies and appraise the future perspectives of cell
therapy.Postnatal Neovascularisation Therapies
Postnatal neovascularisation refers to the process of new
vessel formation in the adult. In the past decade, new
insights into this process have arisen, and therapies stim-
ulating postnatal neovascularisation, that is, growth-factor
therapy and stem cell therapy, have been studied both in
preclinical and clinical settings.
Growth-factor therapy augments postnatal neo-
vascularisation by supplying proangiogenic growth factors,
such as vascular endothelial growth factor (VEGF), fibroblast
growth factor (bFGF) or hepatocyte growth factor (HGF), to
the ischaemic tissue either in the form of a recombinant
protein or by means of gene therapy to introduce genes
encoding for such a pro-angiogenic factor. In total, eight
patients’ series and four randomised controlled trials have
reported on the use of growth-factor therapy in CLI patients.
Initial uncontrolled studies investigating growth-factor
therapy in patients with CLI showed promising results.
However, larger randomised trials in patients with CLI and
intermittent claudication were mainly disappointing and
reported only limited success18,19 (see Ref. 20 for further
reading on these trials). Several factors have been suggested
to have negatively influenced the results of the randomised
trials, such as the administered dose, the achieved duration
of gene expression, heterogeneity between patients included
in the trials and poor end point selection.21 Furthermore, the
clinical studies conducted thus far have only focussed on the
induction of a single proangiogenic factor, while the induc-
tion of a single growth factor may be insufficient to drive the
postnatal neovascularisation process. Interestwithin the fieldof growth-factor therapy now appears to be shifting to the
induction of more than one single proangiogenic factor, and
randomised placebo-controlled trials are currently focussing
on the effects of gene transfer of key transcription factors,
such as hypoxia-inducible factor (HIF)-1a.22
After the discovery of bone marrow-derived endothelial
progenitor cells (EPCs) in peripheral blood in the 1990s, many
publications reported on the role of EPCs in postnatal neo-
vascularisation. The mechanisms by which EPC augment
postnatal neovascularisation are thought to be, on the one
hand, by homing and direct incorporation into existing blood
vessels, facilitating the sprouting of new capillaries, and, on
the other hand, by paracrine effects, stimulating resident
endothelial cells in the vascular wall to proliferate.23e31
Initial clinical studies on the effects of stem or progenitor
cell therapy in patients with PAD or CLI showed encouraging
results. Thus far, over 30 clinical studies reported on the use
of bone marrow-derived or peripheral blood-derived stem
cells in patients with PAD and CLI, most of them reporting
improvements in clinical parameters, such as rest pain, pain-
free walking distance, ankleebrachial pressure index and/or
transcutaneous oxygen pressure (see Ref 32 for an in-depth
review of these studies).Stem Cell Therapy for PAD: Where Do We
Stand?
Majority of studies on cell therapy in PAD have been small
studies in CLI patients, lacking double-blind controls.
Large, randomised, placebo-controlled trials are needed to
confirm the results of the initial case reports and patient
series. Currently, eight randomised, placebo-controlled
clinical trials on the effects of stem cell therapy in
patients with CLI are being conducted worldwide; of which
four are European, investigator-driven trials (see Table 1).
Of note, most of the reported studies investigating the
effects of stem cell therapy in CLI patients have been
conducted in relatively young Asian patients with throm-
boangiitis obliterans.33 In Caucasian patients however, the
main cause of CLI is atherosclerotic PAD, which is associ-
ated with a high presence of cardiovascular risk factors.
These cardiovascular risk factors have been reported to
impair the functional capacities of stem and progenitor
cells34 and may negatively influence the effects of stem cell
therapy. It is therefore important to evaluate the effects of
stem cell therapy also in Westernised populations. The
ongoing randomised clinical trials mentioned in Table 1 will
provide initial insights into the efficacy of stem cell therapy
in atherosclerotic PAD patients.
Further fundamental as well as clinical research is neces-
sary to answer the many unanswered questions regarding
stem cell therapy e the optimal cell population to be
administered, the optimal route of administration, the
optimal dose, patient selection criteria32 e and to develop
optimised, well-tailored stem cell therapy for PAD patients.
Several different cell populations have been used in clinical
studies and were reported beneficial; however, no direct
comparison between cell types has been performed in a clin-
ical study so far. In general, it is currently believed that
different cell populationswork together in vascular repair and
postnatal neovascularisation, and that these cells act via
Table 1 Currently ongoing randomised, placebo controlled trials investigating the effects of stem cell therapy in CLI patients.
Year started Name (NCT) Number of patients Country Intervention
2006 JUVENTAS Trial (00371371) 110e160 The Netherlands Intra-arterial BM-MNC
2007 BONMOT Trial (00434616) 90 Germany Intramuscular BM-MNC
2007 RESTORE-CLI Trial (00468000) 150 United States
of America
Intramuscular ‘‘Aastrom TRC’’ BM cells
2007 Harvest Technologies (00498069) 48 United States
of America
Intramuscular BM aspirate concentrate
2007 ABC Trial (00539266) 108 The Netherlands Intramuscular BM-MNC
2007 ACT34-CLI Trial (00616980) 75 United States
of America
Intramuscular CD34þ cells
2008 MESENDO Trial (00721006) 30 United States
of America
Intramuscular ‘‘stem cell mixture’’
2009 BALI Trial (00904501) 110 France ‘‘Implantation’’ of BM-MNC
Overview consists of all relevant trials registered in the US NIH trial register (clinictrials.gov).
NCT Number: Study identification number in the clinical trial register of the U.S. National Institutes of Health (clinicaltrials.gov).
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lial differentiation, by supplying angiogenic factors via
a paracrine mechanism to resident cells or by a combination
of both. The synergy of different cell types remains to be
clarified, which may lead to the identification of the most
potent (combination of) cell types to be used for stem cell
therapy.
Both intramuscular injection of cells, intra-arterial
injection, or the combination of both have been reported
as effective ways to administer stem cell therapy. With
intramuscular injection, local depots of stem cells are
created in the ischaemic muscle, which could augment
neovascularisation by facilitating cell-to-cell contact, cell
transdifferentiation and paracrine mechanisms; but survival
of the stem cell may be reduced since the depots are laid
down in an ischaemic environment. With intra-arterial
administration, stem cells travel to the border zone of
ischaemia in the nutrient- and oxygen-rich circulation, thus
providing a favourable environment for survival and
engraftment, but cell uptake from the circulation to the
ischaemic tissue may be limited. Clinical studies comparing
different routes of administration have not yet been repor-
ted but will help to identify the most effective way of
delivering stem cell therapy to the ischaemic tissue.
Remarkable differences in the number of stem cells
isolated from the bone marrow and in the numbers of
administered cells have been reported between studies,
with a range of approximately 125-fold for the number of
isolated cells. However, no relation between this varying
cell dose and the obtained effects has been observed
between these studies. A dose-escalating study investi-
gating the effects of increasing numbers on injected cells
will allow further optimisation of stem cell therapy.
It is still largely unknown what determines the efficacy
of stem cell therapy in a patient. Preclinical and clinical
results hint at the influence of the patient’s age, the
severity of the disease, the presence of risk factors such as
diabetes, hypertension and smoking behaviour and the
degree of stem cell dysfunction. In fact, a direct relation
between the number of cardiovascular risk factors and the
number of EPCs and their function has been demonstratedin patients with cardiovascular disease.34e39 Further
research on the influence of patient characteristics on the
effects of stem cell therapy will help to determine patient
suitability for stem cell therapy.Future Perspectives
Both growth factor and cell therapy appear to be promising
strategies to augment neovascularisation in CLI patients. The
therapies are still being developed and optimised, hopefully
leading to better tailored treatment for PAD patients in
general, and for patients with CLI specifically.
A logical direction for future research may be to combine
growth factor and cell-based therapy. Intramuscular gene
therapy could be administered in the calf muscles as pre-
treatment of the target tissue to augment homing of intra-
arterially administered progenitor cells. Furthermore, gene
therapy of progenitor cells ex vivo could be applied before
injecting them into the patient to enhance the homing,
migration, incorporation and/or (trans)differentiation
capacities. In addition, progenitor cell dysfunction may be an
interesting therapeutic target. Despite the promising effects
reported for autologous cell therapy, the fact that functional
capacities of progenitor cell from patients with cardiovas-
cular disease are hampered is becoming more and more
apparent, as are the negative effects of cardiovascular risk
factors on the function of these cells. Hampered functional
capacities, such as impaired homing to ischaemia, and
reduced vascular outgrowth might limit the effects of cell
therapy. It has been demonstrated that these EPC dysfunc-
tions can be (partially) reversed by systemic pharmacological
interventions with statins,40 peroxisome proliferator-
activated receptor (PPAR) gamma agonists,41 erythropoi-
etin42 or angiotensin II receptor antagonists.43 Besides the
already known benefits of risk-factor management, this
underscores the importance of strict treatment of cardio-
vascular risk factors in PAD patients. Furthermore, ex vivo-
pre-treatment of progenitor cells with drugs targeting
cardiovascular risk factors, such as statins and certain anti-
hypertensive drugs, has been shown to improve cellular
Stem Cell Therapy in PAD S41function in vitro and increase neovascularisation capacity in
vivo.40,44e50 Thus, not only the treatment of cardiovascular
risk factors supplemental to stem cell therapy, but also
administration of pre-treated, functionally improved autolo-
gous stem cells might further augment the efficacy of stem
cell therapy.
In vitro selection of cells may be another option to
further optimise stem cell therapy. The exact (combination
of) cell types responsible for the effects of cell therapy is not
yet known, but selection of proangiogenic cell types and
filtering out unwanted or undesirable (possibly pro-
atherosclerotic) cells may improve therapeutic efficacy. In
culture conditions, different methods can lead to outgrowth
of cells with an endothelial phenotype. Early outgrowth EPC
can be cultured in 4e7 days by plating mononuclear cells in
a specific medium that facilitates endothelial outgrowth.23
These cells are mostly monocyte-derived and seem to act
mainly by the secretion of proangiogenic factors.51 Preclin-
ical studies showed beneficial effects of these EPCs in
models of hindlimb ischaemia.52 Late outgrowth EPC emerge
in culture after 3e4 weeks as colonies of confluent,
cobblestone-shaped cells with robust proliferative
capacity.53 They most likely derive from a CD34þ cell pop-
ulation and act by incorporating in newly formed vascula-
ture. While ex-vivo cultured early outgrowth EPCs have been
applied clinically, late outgrowth EPCs have not been used in
the clinic yet, but seem promising because of their profound
proliferative capacity and the already obtained preclinical
effects. In-vitro differentiation towards an endothelial
progenitor cell type may thus further augment the effects of
cell therapy.
Although the need for new revascularisation options in
‘no-option’ CLI patients is high and current evidence for the
efficacy of therapeutic neovascularisation is appealing, the
possibility of side effects should not be disregarded. Thus
far, the number and extent of reported side effects is
minimal, but no sufficiently long-term follow-up of patients
treated with such cell therapy is currently available.
Continued monitoring and long-term follow-up of all
patients treated with stem cell therapy is warranted to
provide solid ground for long-term safety conclusions.
Until now, the effects of postnatal neovascularisation
therapy have predominantly been studied in no-option CLI
patients, which is a patient group in urgent need of such
new treatment options. Furthermore, no-option CLI
patients form, by definition, a patient group in which
neovascularisation therapy will not interfere with conven-
tional treatment options, and hence will not delay
a possible limb salvaging therapy. By contrast, the
hampered functional capacities of stem cells of CLI patients
might render no-option CLI patients less suited as the initial
patient group in which to study the effects of neo-
vascularisation therapy. However, it should be noted that
not all no-option patients are incurable, since no-option
patients also include patients who are inoperable due
extensive co-morbidity, but in which an amputation is not
inevitable per se. Furthermore, the results obtained in CLI
patients thus far have also led to the initiation of cell
therapy studies in patients with less severe stages of PAD,
such as intermittent claudication. Intermittent claudication
patients differ substantially from CLI patients, with regard
to the severity of PAD (non-end-stage disease), the amountof vascular damage and the possibly different extent of
stem cell dysfunction. These studies will provide insights in
the effects of such patient and disease characteristics on
the effectiveness of stem cell therapy.
In summary, postnatal neovascularisation by means of
growth factor therapy, cell-based therapy or a combination
of both, appears to be a viable alternative in the treatment
of CLI patients without other treatment options. Ongoing
randomised clinical trials and new (pre)clinical studies
further elucidating underlying mechanisms of postnatal
neovascularisation will hopefully lead to crucial advances in
the treatment of PAD in the near future.
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